Most cancer-associated deaths occur due to metastasis, yet our understanding of metastasis
as an evolving, heterogeneous, systemic disease and of how to effectively treat it is still …

The TP53 tumor suppressor is the most frequently altered gene in human cancers, and has
been a major focus of oncology research. The p53 protein is a transcription factor that can …

Although p53 inactivation promotes genomic instability and presents a route to malignancy
for more than half of all human cancers,, the patterns through which heterogenous TP53 …

Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic disease refractory to all
targeted and immune therapies. However, our understanding of PDAC microenvironment …

Intratumour heterogeneity (ITH) is a hallmark of cancer that drives tumour evolution and
disease progression. Technological and computational advances have enabled us to …

Immunotherapies have shown benefits across a range of human cancers, but not pancreatic
ductal adenocarcinoma (PDAC). Recent evidence suggests that the immunosuppressive …

Broad-spectrum RAS inhibition holds the potential to benefit roughly a quarter of human
cancer patients whose tumors are driven by RAS mutations1, 2. RMC-7977 is a highly …

RAS and MYC rank amongst the most commonly altered oncogenes in cancer, with RAS
being the most frequently mutated and MYC the most amplified. The cooperative interplay …

C-Myc overexpression contributes to multiple hallmarks of human cancer but directly
targeting c-Myc is challenging. Identification of key factors involved in c-Myc dysregulation is …

Pancreatic ductal adenocarcinoma (PDAC) is clinically challenging due to late diagnosis
and resistance to therapy. Two major PDAC subtypes have been defined based on …